Patent · US Expired

Prothrombin derivatives

US6086871A · kind A · utility

20Cited by

0References

22Claims

0Family size

Assignee

Baxter Aktiengesellschaft · AT

Inventors

Bernhard Fischer · Wien, AT
Uwe Schlokat · Orth an der Donau, AT
Artur Mitterer · Orth an der Donau, AT
Falko-Günter Falkner · Orth an der Donau, AT
Johann Eibl · Wien, AT

Key dates

Filing date	Jan 26, 1998
Grant date	Jul 11, 2000
Priority date	—
Expiry date	Jan 26, 2018

Classification

Technology area (CPC G)Physics
CPC primaryG01N2333/974
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to new prothrombin mutants or derivatives thereof which comprise one or more changes in their protein sequence as compared to natural protein, are either inactive or have an activity of approximately 10% at the most, preferably approximately 0.25% at the most, of the natural protein and which have a binding capacity relative to natural ligands (natural or synthetic anticoagulants) substantially corresponding to that of the natural protein. Furthermore, the use of mutated prothrombin mutants or derivatives, respectively, as pharmaceutical preparations is described.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.